Albumin in Cirrhosis and SBP Clinical Trial
Effect of Intravenous Albumin on Renal Impairment and Mortality in Patients with Cirrhosis and Spontaneous Bacterial Peritonitis Multi-center, open-label (analyst-blinded), randomised controlled trial Objective: To assess use of IV albumin for reducing renal impairment and mortality when compared to antibiotics alone in patients with cirrhosis and SBP. 126 Patients cirrhosis and SBP (PMN cell count in the ascitic fluid > 250 mm3) were randomized to 廁 Cefotaxime + albumin (n=63) Primary Outcomes GD Cefotaxime (n=63) 10% 33% Renal impairment P=0.002 10% 29% Hospital mortality P=0.01 22% 41% All-cause mortality P=0.03 IV albumin reduces the incidence of renal impairment and mortality when compared to antibiotics alone among patients with cirrhosis and spontaneous bacterial peritonitis Sort P, et al. NEJM, 1999. 341(6):403-409.